Collegium Pharmaceutical, Inc. (COLL)

Over the past six months, Collegium Pharmaceutical's stock has been impacted by several events, including the Q3 2025 earnings report where the EPS beat analysts' expectations, and the Q2 2025 financial results where the company reported record quarterly net revenue. The company announced its 2026 full-year financial guidance, projecting net product revenues between $805 million and $825 million. The company closed a $980 million syndicated credit facility. Several individual insiders and institutional entities engaged in selling company stock between August and December 2025. Collegium Pharmaceutical, Inc.'s stock price increased by 52.78% over the last year.

There is some seasonality in the demand for Collegium Pharmaceutical's products, particularly for Jornay PM, with the company anticipating a strong back-to-school season and second half of the year. This suggests that demand for its ADHD medication, Jornay PM, may increase during periods associated with the academic calendar.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for serious medical conditions, with a strong emphasis on responsible pain management and an expanding presence in neuropsychiatry. The company operates within the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry. Collegium utilizes its patented DETERx platform technology to create abuse-deterrent products designed to maintain the extended-release and safety profiles of abused drugs.

Collegium Pharmaceutical, Inc. is headquartered in Stoughton, Massachusetts, United States. The information details its US-based operations and market focus, and does not explicitly outline a broader international geographic footprint.

Collegium Pharmaceutical appears to maintain a positive brand reputation, particularly in its commitment to responsible pain management and its expansion into neuropsychiatry. The company emphasizes its dedication to improving the lives of people with serious medical conditions and its values of integrity, embracing differences, encouraging expression, and accountability. There are no specific events in the past year highlighted that have negatively impacted Collegium Pharmaceutical, Inc.'s brand reputation.

Collegium Pharmaceutical, Inc. has a diverse ownership structure. Institutions hold a significant majority of the shares, with approximately 87.7% of the company owned by institutions. Hedge funds own about 11.5%, while individual insiders hold a smaller percentage at 0.683%. Major institutional owners include BlackRock, Inc., Rubric Capital Management LP, and Eventide Asset Management, LLC. Individual insiders have primarily been selling shares in the past three months.